首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   27041篇
  免费   2244篇
  国内免费   44篇
耳鼻咽喉   251篇
儿科学   1068篇
妇产科学   771篇
基础医学   3643篇
口腔科学   409篇
临床医学   3726篇
内科学   4669篇
皮肤病学   284篇
神经病学   2608篇
特种医学   734篇
外国民族医学   1篇
外科学   2539篇
综合类   879篇
一般理论   66篇
预防医学   3510篇
眼科学   529篇
药学   1712篇
中国医学   12篇
肿瘤学   1918篇
  2022年   141篇
  2021年   402篇
  2020年   297篇
  2019年   429篇
  2018年   455篇
  2017年   378篇
  2016年   427篇
  2015年   528篇
  2014年   693篇
  2013年   1110篇
  2012年   1557篇
  2011年   1627篇
  2010年   817篇
  2009年   754篇
  2008年   1449篇
  2007年   1603篇
  2006年   1552篇
  2005年   1537篇
  2004年   1563篇
  2003年   1474篇
  2002年   1453篇
  2001年   518篇
  2000年   485篇
  1999年   476篇
  1998年   342篇
  1997年   301篇
  1996年   325篇
  1995年   276篇
  1994年   245篇
  1993年   247篇
  1992年   372篇
  1991年   374篇
  1990年   366篇
  1989年   358篇
  1988年   318篇
  1987年   315篇
  1986年   305篇
  1985年   282篇
  1984年   255篇
  1983年   271篇
  1982年   187篇
  1981年   182篇
  1980年   154篇
  1979年   241篇
  1978年   170篇
  1977年   138篇
  1976年   148篇
  1974年   131篇
  1973年   107篇
  1972年   117篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
ABSTRACT

Measuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised.  相似文献   
4.
ABSTRACT

This work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated.  相似文献   
5.
6.
7.

Background

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods

Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results

Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions

No safety concerns arose, supporting the favorable benefit-risk profile of RZV.  相似文献   
8.
9.
10.
ABSTRACT

Forensic DNA analysis is dependent on comparing the known and the unknown. Expand the number of known profiles, and the likelihood of a successful match increases. Forensic use of DNA is moving towards comparing samples of unknown origin with publicly available genetic data, such as the records held by genetic genealogy providers. Use of forensic genetic genealogy has yielded a number of recent high-profile successes but has raised ethical and privacy concerns. Navigating family trees is complex, even more so when combined with a comparison of genetic relationships. This intelligence-gathering process has led to occasional false leads, and its use also risks a public backlash, similar to concerns over Cambridge Analytica. A cautious approach to use of this technique is therefore warranted.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号